Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Long Term Survivors with Metastatic Pancreatic Cancer Treated with Gemcitabine Alone or Plus Cisplatin: a Retrospective Analysis of an Anatolian Society of Medical Oncology Multicenter Study

  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The majority of patients with pancreatic cancer present with advanced disease. Systemic chemotherapy has limited impact on overall survival (OS) so that eligible patients should be selected carefully. The aim of this study was to analyze prognostic factors for survival in Turkish advanced pancreatic cancer patients who survived more than one year from the diagnosis of recurrent and/or metastatic disease and receiving gemcitabine (Gem) alone or gemcitabine plus cisplatin (GemCis). Methods: This retrospective evaluation was performed for patients who survived more than one year from the diagnosis of recurrent and/or metastatic disease and who received gemcitabine between December 2005 and August 2011. Twenty-seven potential prognostic variables were chosen for univariate and multivariate analyses to identify prognostic factors associated with survival. Results: Among the 27 variables in univariate analysis, three were identified to have prognostic significance: sex (p = 0.04), peritoneal dissemination (p =0.02) and serum creatinine level (p=0.05). Multivariate analysis by Cox proportional hazard model showed only peritoneal dissemination to be an independent prognostic factor for survival. Conclusion: In conclusion, peritoneal metastasis was identified as an important prognostic factor in metastatic pancreatic cancer patients who survived more than one year from the diagnosis of recurrent and/or metastatic disease and receiving Gem or GemCis. The findings should facilitate pretreatment prediction of survival and can be used for selecting patients for treatment.

Keywords

References

  1. Burris HA III, Moore MJ, Andersen J, et al (1997). Improvements in survival and clinical benefit with gemcitabine as first-line chemotherapy for patient with advanced pancreas cancer: a randomised trial. J Clin Oncol, 15, 2403-13. https://doi.org/10.1200/JCO.1997.15.6.2403
  2. Colucci G, Giuliani F, Gebbia V, et al (2002). Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the gruppo oncologico dell'Italia Meridionale. Cancer, 94, 902-10. https://doi.org/10.1002/cncr.10323
  3. Cooperman AM (2001). Pancreatic cancer: the bigger picture. Surg Clin North Am, 81, 557-74. https://doi.org/10.1016/S0039-6109(05)70143-2
  4. Engelken FJ, Bettschart V, Rahman MQ, et al (2003). Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol, 29, 368-73. https://doi.org/10.1053/ejso.2002.1405
  5. Goulart BH, Clark JW, Lauwers GY, et al (2009). Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol, 16, 2-13.
  6. Heinemann V, Labianca R, Hinke A, et al (2007). Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: Pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol, 18, 1652-9. https://doi.org/10.1093/annonc/mdm283
  7. Heinemann V, Quietzsch D, Gieseler F, et al (2006). Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol, 24, 3946-52. https://doi.org/10.1200/JCO.2005.05.1490
  8. Ikeda M, Okada S, Tokuuye K, et al (2001). Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer, 91, 490-5. https://doi.org/10.1002/1097-0142(20010201)91:3<490::AID-CNCR1027>3.0.CO;2-L
  9. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 59, 225-49.
  10. Marechal R, Demols A, Gay F, et al (2007). Prognostic factors and prognostic index for chemonaïve and gemcitabinerefractory patients with advanced pancreatic cancer. Oncology, 73, 41-51 https://doi.org/10.1159/000120627
  11. Nakachi K, Furuse J, Ishii H, et al (2007). Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol, 37, 114-20. https://doi.org/10.1093/jjco/hyl144
  12. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology: Pancreatic adenocarcinoma version 2.2012. Fort Washington, PA, National Comprehensive Cancer Network, 2012
  13. Papadoniou N, Kosmas C, Gennatas K, et al (2008). Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. Anticancer Res, 28, 543-9.
  14. Royal RE, Wolff RA, Crane CH (2011). Cancer of the pancreas. In: DeVita VT, Hellman S, Rosenberg SA editors. Cancerprinciples and practice of oncology. 9th ed. Philadelphia: Lippincott and Wilkins, 2011, 61-989.
  15. Ryan DP, Grossbard ML (1998). Pancreatic cancer:local success and distant failure. Oncologist, 3, 178-88.
  16. Shimoda M, Katoh M, Kita J, et al (2010). The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer. Chemotherapy, 56, 501-6. https://doi.org/10.1159/000321014
  17. Ueno H, Okada S, Okusaka T, et al (2000): Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology, 59, 296-301. https://doi.org/10.1159/000012186
  18. Viret F, Ychou M, Lepille D, et al (2004). Gemcitabine in combination with cisplatin versus gemcitabine alone in the treatment of locally advanced or metastatic pancreatic cancer: final results of a multicenter randomized phase II study. Proc Am Soc Clin Oncol, 22, 4118. https://doi.org/10.1200/jco.2004.22.14_suppl.4118
  19. Yi JH, Lee J, Park SH, et al (2011). A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Oncology, 80, 175-80. https://doi.org/10.1159/000328449

Cited by

  1. Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7119
  2. Clinical Characteristics of Long-Term Survivors of Inoperable Pancreatic Cancer vol.43, pp.7, 2014, https://doi.org/10.1097/MPA.0000000000000163
  3. Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis vol.63, pp.8, 2014, https://doi.org/10.1007/s00262-014-1554-7
  4. Epidemiology of Pancreatic Cancer in Vojvodina Province in Serbia vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10779